QUOTE AND NEWS
StreetInsider.com  Jul 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ceres+%28CERE%29+to+Expand+Brazil+Product+Development+Programs+and+Sorghum%2C+Sugarcane+Trait+Development/9692988.html for the full story.
Forbes  Jul 24  Comment 
Utilities in states with progressive policies are leading sales of renewable energy and leading in savings from energy efficiency, according to a report released today by Ceres, a non-profit that seeks to mobilize leadership on clean energy. And...
Biomass Magazine  Jul 15  Comment 
Ceres Inc. has released its fiscal third quarter 2014 financial results, reporting revenue of $800,000 for the three months ended May 31. The company also announced progress with its sorghum evaluations in Brazil.
SeekingAlpha  Jul 11  Comment 
Ceres, Inc. (NASDAQ:CERE) Q3 2014 Earnings Conference Call July 10, 2014, 16:30 PM ET Executives Gary Koppenjan - Director of IR and Communications Richard Hamilton - President and CEO Paul Kuc - CFO Analysts Caleb Dorfman...
Biomass Magazine  Jul 9  Comment 
Ceres Inc., an agricultural biotechnology and seed company, has announced that the company has licensed its Persephone genome visualization application to Bayer CropScience. The software was originally developed for in-house use by Ceres.
StreetInsider.com  Jul 9  Comment 
The Trading Radar highlights key earnings and economic announcements for the next trading session: Before Markets Open: Economics: 8:30am EDT Initial Claims - Street sees 311K Continuing Claims - Street sees 2.567M Earnings: Family Dollar...
StreetInsider.com  Jul 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Ceres+%28CERE%29+Licensed+Its+Software+to+Bayer+CropScience/9644566.html for the full story.
Biomass Magazine  Jun 13  Comment 
Ceres Inc. will evaluate a number of its biotech traits in sugarcane in South America. Plantings were recently completed and preliminary performance observations will be available by the end of the year.
Biomass Magazine  May 8  Comment 
Ceres Inc. is expanding its current research activities in Mexico. The company's northern hemisphere plant breeding sites complement its product development activities in Brazil, where the company is commercializing sorghum hybrids.




 

Ceres (NASDAQ:CERE) is a biotechnology company which focuses on agriculture. Ceres sells seeds used to grow plants dedicated for use as biofuel. The seeds Ceres makes are bred to have low inputs, are weather hardy, and can grow at large scales. These dedicated plants compete with corn and sugarcane which are often used as fuelstock.[1]


Business Overview

For the full year ended in August 2011, Ceres reported a total revenue of $6.6M. During the period, the company reported a net loss of $36.3M. This compares with $6.6M in revenue in 2010 and a net loss of $22.6M. The majority of the revenue was from collaborative research and government grants while the largest cost was from research and development. [2]

New Updates

The company's initial public offering of stock on the NASDAQ occurred on February 21, 2012. The company offered 5M shares each for $13. This was below the $16-$17 revised price range. The company was originally planning to price between $21-$23. The deal raised a total of $65M. The lead mangers of the deal were Goldman Sachs Group (GS) and Barclays.[3]

Trends & Forces

Dependence on Government Grants

Historically, much of Ceres' revenue has been from government grants. This is part of the US government's goal to encourage the growth in biofuels. If these subsidies are removed, then Ceres will be impacted. This could happen if alternate forms of energy are discovered or if demand for a decrease in overall government spending rises. [4]


  1. CERE S-1/A 2012 PROSPECTUS SUMMARY "Our Company" pg 1
  2. CERE S-1/A 2012 PROSPECTUS SUMMARY "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 10
  3. Renaissance Capital - IPO Home "Ceres prices IPO at $13, below revised range; insiders expected to have purchased 20% of the deal" 22 Feb 2012
  4. CERE S-1/A 2012 PROSPECTUS SUMMARY "RISK FACTORS" pg 13-21
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki